Targeted drug achieves 43% response rate in KRAS-mutated lung cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a new study.
Materials provided by Dana-Farber Cancer Institute. Note: Content may be edited for style and length.
Source link aaaaa